Allergen-specific immunotherapy with recombinant grass pollen allergens

Area of Science:

• Immunology
• Allergology
• Biotechnology

Background:

• Allergen-specific immunotherapy traditionally uses natural extracts to manage allergic responses.
• Recombinant DNA technology allows for the production of specific allergens, enhancing research into improved immunotherapy.

Purpose of the Study:

• To evaluate the efficacy of a 5-recombinant grass pollen allergen mixture in alleviating symptoms and reducing medication requirements in grass pollen-allergic individuals.
• To assess the impact on quality of life and immune responses.

Main Methods:

• A randomized, double-blind, placebo-controlled subcutaneous immunotherapy trial was conducted.
• Participants had allergic rhinoconjunctivitis, with or without asthma.
• Key measures included a symptom-medication score, quality of life questionnaire, conjunctival provocation tests, and specific antibody analysis.

Main Results:

• Significant reductions in both symptoms and medication use were observed in the recombinant allergen group compared to placebo.
• Clinically relevant improvements in quality of life were reported.
• Strong allergen-specific IgG(1) and IgG(4) antibody responses were induced, even in some individuals not initially sensitized to specific components like Phl p 5.

Conclusions:

• A vaccine composed of recombinant allergens is a safe and effective treatment for allergic rhinitis symptoms.
• Clinical benefits correlate with immune response modulation, including increased IgG(4) and decreased IgE, suggesting the induction of regulatory T cells.